Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Treatment of rhTPO for Chemoradiation Induced Thrombocytopenia in Cervical Squamous Cell Carcinoma
NCT07649395Completed
- Sponsor
- Meifeng Biopharma
- Start
- Feb 2021
- Primary completion
- Jun 2024
- Countries
- 1
01
Overview
Trial of recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia (CIT) (2 arms), sponsored by Meifeng Biopharma. Primary endpoint: Incidence of severe Cancer Treatment-Induced Thrombocytopenia (Grade 3 - Grade 5) at 6 months. Started Feb 2021; status: completed.
02
Drugs
recombinant human thrombopoietin
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on NCT07649395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07649395.